Explore glutathione and NAD+ development concepts, with a separate scientific review area for peptide and pharmaceutical oral film proposals.
Glutathione and NAD+ are shown as ingredient development concepts, subject to market and formulation review. The eight additional peptide topics below are scientific review subjects. Their inclusion does not confirm oral-film feasibility, stock, manufacturing capability for that active, or authorization to supply a human-use product.
No validated per-strip strengths are published. Research and drug-development topics are kept separate from the nutrition concept catalogue. The photographs are generated illustrative development scenes and packaging concepts; they are not evidence of an active-containing product or a completed study.
Glutathione is a tripeptide. This standalone concept is distinct from our existing glutathione and vitamin C combination. Confirm the exact material form and its destination-market eligibility before developing a consumer product.
NAD+ is a dinucleotide coenzyme, not a peptide. It is included here as an adjacent advanced oral film concept. NAD+, NADH, NMN and nicotinamide riboside are different materials; the project must identify the intended substance precisely.
These topics are not retail products, dietary-supplement recommendations or confirmed manufacturing offers. A legitimate research or pharmaceutical development inquiry must be evaluated on its own purpose, sponsor, evidence and permissions. No human-use instructions or dosing are provided.
FDA highlights limited safety information and peptide characterization concerns for BPC-157.
Define the proposed purpose, exact material and evidence package before considering any formulation study.
FDA describes limited clinical information and reported safety concerns for CJC-1295.
Resolve exact chemical identity and the intended project pathway before scope assessment.
FDA identifies concerns for injectable GHK-Cu. That route-specific information does not validate an oral film.
Review the copper-peptide identity, intended route and applicable evidence; cosmetic use does not establish oral eligibility.
The cited VYLEESI label describes subcutaneous bremelanotide, not an oral strip.
Any oral film proposal requires a separate dosage-form, evidence and authorization review.
FDA identifies TB-500 as a thymosin beta-4 fragment and notes insufficient human safety information.
Confirm the exact sequence and material identity; do not assume that a trade name identifies a qualified ingredient.
The cited oral semaglutide labeling concerns tablets; it does not validate a custom dissolving strip.
A film proposal requires its own evidence and regulatory pathway. No tablet-to-strip or injection-to-strip equivalence is implied.
The cited MOUNJARO labeling describes subcutaneous injection, not oral film administration.
Review the sponsor, applicable permissions and dosage-form evidence before any development commitment.
FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under US federal law.
Included for scientific context only. No consumer product, sample or commercial oral-strip supply is offered here.
| Ingredient identity | Exact substance, form, material specification and supplier documentation |
|---|---|
| Project pathway | Target market, proposed classification, sponsor and applicable research or manufacturing permissions |
| Film feasibility | A study question and agreed acceptance criteria for film characteristics and ingredient content |
| Evidence boundaries | Dissolution data do not establish clinical absorption, therapeutic effect or dose equivalence |
| Package protection | A defined package compatibility and stability study scope |
| Decision to proceed | Written technical and market review before samples, production or a commercial commitment |
Reviewed October 8, 2026. The US sources explain specific evidence and regulatory boundaries; they are not a worldwide authorization assessment. Destination-market requirements and project-specific documents control any decision to proceed.
Share your organization, target market, exact ingredient identity and intended project scope. Project acceptance and any supply depend on technical review, documented responsibilities and applicable permissions.
Standalone glutathione and NAD+ concepts are shown for ingredient, market and formulation review. Neither page establishes a validated strength, finished-stock supply or universal market eligibility. NAD+ is a coenzyme, not a peptide.
No. The review topics are not consumer product offers. They require project-specific scientific and regulatory assessment. Retatrutide is shown only for scientific context and is not offered for oral-strip supply.
No. A requested amount is a development input. Film feasibility, content uniformity, stability, route-specific evidence and the applicable authorization pathway require separate assessment.
Generated illustrative development scenes and packaging concepts. They do not establish ingredient content, facility identity, completed tests or approved human-use products.
WhatsApp
